ANDA 206049, held by Actavis Laboratories FL. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 206049 (Methylphenidate Hydrochloride), held by Actavis Laboratories FL, was first approved by FDA on May 17, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylphenidate Hydrochloride5MG/ML · for suspension, extended release;oral | Methylphenidate Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters